nalbuphine HCl ER

DRUG3 trials

Sponsors

Trevi Therapeutics

Conditions

Nodularis PrurigoPrurigoPrurigo NodularisPruritusUremic Pruritus

Phase 1

Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

CompletedNCT02373215

Trevi TherapeuticsUremic Pruritus

Start: 2013-04-30End: 2013-11-30Updated: 2025-05-22

Phase 2

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

CompletedNCT02143973

Trevi TherapeuticsPruritus, Uremic Pruritus

Start: 2014-09-30End: 2016-01-31Updated: 2025-05-21

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

CompletedNCT02174432

Trevi TherapeuticsNodularis Prurigo, Prurigo, Prurigo Nodularis

Start: 2015-08-15End: 2017-09-03Updated: 2025-05-21

Related Papers

A population pharmacokinetic–pharmacodynamic model evaluating efficacy of nalbuphine extended‐release in patients with prurigo nodularis

British Journal of Clinical Pharmacology2023-01-211 citations